Qtron Investments LLC Sells 2,854 Shares of AbbVie Inc. $ABBV

Qtron Investments LLC lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 12.5% during the 4th quarter, HoldingsChannel reports. The firm owned 20,065 shares of the company’s stock after selling 2,854 shares during the period. AbbVie comprises approximately 0.6% of Qtron Investments LLC’s holdings, making the stock its 23rd largest holding. Qtron Investments LLC’s holdings in AbbVie were worth $4,585,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the business. Chelsea Counsel Co. acquired a new stake in AbbVie in the 3rd quarter valued at approximately $26,000. Westend Capital Management LLC acquired a new stake in AbbVie in the 4th quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX acquired a new stake in AbbVie in the 3rd quarter valued at approximately $31,000. Legacy Wealth Managment LLC ID raised its position in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after buying an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC raised its position in AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after buying an additional 85 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ABBV. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, June 7th. Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price on the stock in a research report on Thursday, April 30th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Barclays began coverage on AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $240.00 target price on shares of AbbVie in a research report on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and media coverage highlighted AbbVie’s Skyrizi and Rinvoq as key growth drivers, noting strong first-quarter performance and the potential for continued sales momentum through 2026, including additional indications. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Positive Sentiment: Another market commentary framed AbbVie as a growth-pharma stock at a value-pharma price, reinforcing the view that its earnings growth and pipeline may justify the valuation. AbbVie: Growth-Pharma Profile At A Value-Pharma Price
• Positive Sentiment: AbbVie was also featured on CNBC’s “Final Trades”, which can support investor sentiment by keeping the stock in the market spotlight. AbbVie, Devon Energy and more on CNBC’s ‘Final Trades’
• Neutral Sentiment: Several pieces described AbbVie as a stock worth watching or holding after a strong run, with valuation and balance-sheet concerns tempering enthusiasm but not signaling a major change in the business outlook. Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
• Negative Sentiment: AbbVie also faced a FDA Complete Response Letter for its fast-acting neurotoxin TrenibotE, citing manufacturing-related issues. While the letter reportedly raised no safety or efficacy concerns, it delays the program and adds near-term regulatory uncertainty. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Stock Up 0.0%

NYSE:ABBV opened at $225.04 on Friday. The firm has a market capitalization of $397.60 billion, a price-to-earnings ratio of 110.86, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a twelve month low of $181.73 and a twelve month high of $244.81. The stock’s 50 day moving average price is $210.80 and its two-hundred day moving average price is $219.01.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.46 EPS. As a group, analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.